Vera Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: James R. Meyers

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: James R. Meyers”): 58,946,269 for, 157,112 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 17,971,556 for, 25,399 withheld.

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Michael M. Morrissey, Ph.D.

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael M. Morrisey, Ph.D.”): 45,288,710 for, 13,814,671 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 13,688,265 for, 4,284,151 withheld, 24,539 abstained.

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Patrick G. Enright

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: Patrick G. Enright”): 54,697,296 for, 4,406,085 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 16,059,164 for, 1,937,784 withheld, 7 abstained.

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.

Vera Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 56,585,568 for, 2,433,537 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 65 managers: 17,402,386 for, 587,767 against, 25,399 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 184 managers: 37,071,538 for, 1,767,339 against, 3,337,893 withheld, 258 abstained, 162 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Vera Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 61,834,842 for, 44,710 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 17,986,114 for, 80 against, 25,399 abstained.

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.